What is the FDA standard 6-month pediatric exclusivity extension?
FDA grants a “pediatric exclusivity” extension of 6 months to certain drug marketing authorizations when the company completes written pediatric studies required under FDA’s pediatric program. The extra time extends the period during which FDA generally cannot approve competing “same active ingredient” products for the protected use and population. The program is commonly referred to as pediatric exclusivity and the extension is fixed at 6 months when granted.
Which FDA products can get the 6-month pediatric exclusivity extension?
Pediatric exclusivity applies to drug products that are eligible for patent-like exclusivity protections under FDA’s exclusivity framework and that meet the pediatric study requirement. In practice, it is most often discussed alongside exclusivities tied to approval pathways and marketing authorization (for example, exclusivities granted after approval that can be extended by completing pediatric requirements).
What does a company have to do to earn the 6-month extension?
To receive pediatric exclusivity, the sponsor must complete the pediatric study(s) described in the FDA’s pediatric communication (the pediatric study requirement), and submit the results to FDA. FDA then determines whether the submission satisfies the requirement; if it does, the sponsor receives the 6-month extension to the applicable exclusivity period.
How long is the exclusivity extended, and when does the 6 months start?
The extension is a 6-month add-on to the end of the underlying exclusivity period that was otherwise set to expire. The timing depends on when the baseline exclusivity would have ended; the pediatric extension shifts that end date by six months once pediatric exclusivity is granted.
How is pediatric exclusivity different from a new pediatric label or a pediatric-only approval?
Pediatric exclusivity is about extending FDA exclusivity time for eligible products after completion of pediatric studies. Separately, sponsors can also seek labeling updates or pediatric approvals based on study results. Pediatric exclusivity is specifically an exclusivity-extension mechanism; it is not the same thing as gaining pediatric indications by itself.
Does the 6-month extension block all competitors?
It limits FDA’s ability to approve competing products that would rely on the protected drug’s exclusivity for the covered conditions of use, unless a competitor qualifies for an exception or otherwise meets an applicable statutory pathway. The practical effect is similar to other exclusivity protections: competitors can sometimes still pursue approval, but approval may be blocked for the protected period for the relevant indications/uses.
What if the sponsor does not complete the pediatric studies?
If the sponsor does not complete the pediatric studies as required (or does not submit adequate results), FDA will not grant pediatric exclusivity, and the baseline exclusivity end date remains unchanged.
How does this relate to pediatric formulations or dosing studies?
Pediatric exclusivity studies often focus on evidence needed to support safe and effective dosing and use in pediatric patients, which can involve age-appropriate formulations and dosing regimens. The key is that FDA’s pediatric requirement specifies what studies are needed and the sponsor must complete and submit them to qualify for the extension.
What records or documents should you check to confirm pediatric exclusivity?
Look for FDA communications and the label/exclusivity information associated with the product approval, including FDA’s listing of exclusivities and any pediatric exclusivity grants tied to the marketing authorization. The most reliable confirmation comes from FDA’s published exclusivity determinations and the sponsor’s pediatric study submissions/acknowledgments.
Sources
No sources were provided with your question. If you share a link (e.g., FDA page or statutory/regulatory text you’re using), I can tailor the answer and cite it precisely.